With Biosimilars Getting Approval In Europe, Does Roche’s 2016 EPS Face A Meaningful Risk?

+19.38%
Upside
35.18
Market
42.00
Trefis
RHHBY: Roche logo
RHHBY
Roche

Roche_Q5

Have more questions about Roche? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche
Relevant Articles
  1. Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?
  2. Will Roche Stock Rebound To Its 2022 Highs of $50?
  3. Is Roche Stock Undervalued At $33?
  4. What’s Driving Roche Stock?
  5. Company Of The Day: Roche Holdings
  6. What’s Happening With Roche (RHHBY) Stock?

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology